Oncology

News

Job losses loom at Achilles as TIL therapy platform is cut

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping its R&D in tumour-infiltrating lymphocyte (TIL) therapies for

News

Lilly on alert as new Kisqali approval threatens Verzenio

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly.

News

After FDA no, MSD/Daiichi post new data with lung cancer ADC

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line tr

Oncology

Sven Schaffer and Nicole Raleigh interview at ESMO

ESMO 2024 - Sven Schaffer

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.

News

ESMO: Pfizer drug helps cancer patients gain weight

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no a

News

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour

Job losses loom at Achilles as TIL therapy platform is cut

Lilly on alert as new Kisqali approval threatens Verzenio

After FDA no, MSD/Daiichi post new data with lung cancer ADC

ESMO 2024 - Sven Schaffer

ESMO: Pfizer drug helps cancer patients gain weight

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

Oncology

Editor's Picks